FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015348574> ?p ?o ?g. }

• W2015348574 endingPage "632" @default.
• W2015348574 startingPage "626" @default.
• W2015348574 abstract "No AccessJournal of UrologyAdult Urology1 Feb 2011Oral Testosterone With and Without Concomitant Inhibition of 5α-Reductase by Dutasteride in Hypogonadal Men for 28 Days John K. Amory, Mark A. Bush, Hui Zhi, Ralph B. Caricofe, Alvin M. Matsumoto, Ronald S. Swerdloff, Christina Wang, and Richard V. Clark John K. AmoryJohn K. Amory University of Washington, Seattle, Washington More articles by this author , Mark A. BushMark A. Bush GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author , Hui ZhiHui Zhi GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author , Ralph B. CaricofeRalph B. Caricofe GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author , Alvin M. MatsumotoAlvin M. Matsumoto Geriatric Research Education and Clinical Center, Veterans Affairs-Puget Sound Health Care System, Seattle, Washington Financial interest and/or other relationship with GlaxoSmithKline, Solvay, USADA, Merck, PCC and Up to Date. More articles by this author , Ronald S. SwerdloffRonald S. Swerdloff Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California More articles by this author , Christina WangChristina Wang Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California Financial interest and/or other relationship with Clarus Therapeutics. More articles by this author , and Richard V. ClarkRichard V. Clark GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.09.089AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Co-administration of the 5α-reductase inhibitor dutasteride increases the oral testosterone bioavailability in men with experimentally induced hypogonadism. We examined oral testosterone with and without dutasteride administration in hypogonadal men for 28 days. Materials and Methods: We randomly assigned 43 hypogonadal men to twice daily oral doses of 150, 250 or 400 mg testosterone with 0.25 mg dutasteride, 400 mg testosterone alone or 0.25 mg dutasteride alone for 28 days in a multicenter study. Subjects underwent pharmacokinetic profiling of serum hormones on days 1 and 28. A total of 32 men completed all study procedures. Results: Serum testosterone increased in all groups on testosterone compared with that in the dutasteride only group. At the 400 mg dose the combination of testosterone and dutasteride resulted in average testosterone concentrations that were 2.7 and 4.6 times higher than in the testosterone only group on days 1 and 28, respectively (p <0.01). On day 28 average testosterone was 20% to 30% lower in all groups on testosterone and dutasteride, and 50% lower in the testosterone only group compared with day 1. Serum dihydrotestosterone was suppressed in all groups on dutasteride and increased in the testosterone only group. Conclusions: Oral testosterone administration resulted in a therapeutic serum testosterone concentration in hypogonadal men. Dutasteride improved the oral bioavailability of testosterone while suppressing dihydrotestosterone. Compared with day 1, testosterone was decreased after 28 days of administration. Additional study is warranted of oral testosterone with dutasteride for testosterone deficiency. References 1 : Estradiol and testosterone in the male: secretion by human, simian and canine testes. J Clin Invest1972; 51: 824. Google Scholar 2 : Male hypogonadism. In: Principles and Practice of Endocrinology. Edited by . Philadelphia: Lippincott Williams and Wilkins2001: 1125. chapt 115. Google Scholar 3 : Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab2007; 92: 4241. Google Scholar 4 : Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab1996; 81: 4358. Google Scholar 5 : Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab1996; 81: 3578. Google Scholar 6 : Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab2000; 85: 2670. Google Scholar 7 : Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer1999; 35: 1220. Google Scholar 8 : The therapeutic potential of testosterone patches. Exp Opin Invest Drugs1999; 7: 1977. Google Scholar 9 : Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab2000; 85: 2839. Google Scholar 10 : Children's virilization and the use of a testosterone gel by their fathers. Eur J Pediatr2005; 164: 646. Google Scholar 11 : Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod2009; 24: 425. Google Scholar 12 : Liver damage from long-term methyltestosterone. Lancet1977; 2: 262. Google Scholar 13 : Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther2001; 23: 789. Google Scholar 14 : Clinical use and abuse of androgens and antiandrogens. In: Principles and Practice of Endocrinology. Edited by . Philadelphia: Lippincott Williams and Wilkins2001: 1181. chapt 119. Google Scholar 15 : Clinical administration of androgens. Lancet1939; 1: 502. Google Scholar 16 : Plasma androgen levels in men after oral administration of testosterone and testosterone undecanoate. Acta Endocrinol (Copenh)1975; 79: 366. Google Scholar 17 : Oral testosterone in oil plus dutasteride: a pharmacokinetic study in men. J Clin Endocrinol Metab2005; 90: 2610. Google Scholar 18 : Nanomilled oral testosterone plus dutasteride effectively normalizes serum testosterone in normal men with induced hypogonadism. J Androl2008; 29: 222. Google Scholar 19 : Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab2004; 84: 2179. Google Scholar 20 : Therapeutic effectiveness of oral testosterone. Lancet1974; 2: 1473. Google Scholar 21 : Oral testosterone, a reappraisal. Hormone Res1978; 9: 121. Google Scholar 22 : Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study. Ann Rev Respir Dis1988; 138: 886. Google Scholar 23 : Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci2005; 60: 1451. Google Scholar 24 : Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab2004; 89: 503. Google Scholar 25 : Exogenous testosterone alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum testosterone. J Clin Endocrinol Metab2005; 90: 1502. Google Scholar 26 : The influence of finasteride on the development of prostate cancer. N Engl J Med2003; 349: 215. Google Scholar 27 : Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol2009; 55: 1064. Google Scholar 28 : The effects of the dual 5a-reductase inhibitor dutasteride on localized prostate cancer—results from a 4-month pre-radical prostatectomy study. Prostate2006; 66: 1674. Google Scholar 29 : The effect of 5α-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, PSA and sexual function in healthy young men. J Urol2008; 179: 2333. Link, Google Scholar © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 2February 2011Page: 626-632 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.KeywordstestosteronetestishypogonadismdutasterideadministrationoralAcknowledgmentsMarilyn Busher, Kathy Winter and Kathryn Torrez Duncan assisted with study clinical aspects. Part of the study was done at the Clinical Research Center, University of Washington and the General Clinical Research Center, Harbor-UCLA Medical Center. Crystalline T as a hard gelatin capsule and D were provided by GlaxoSmithKline Research and Development.MetricsAuthor Information John K. Amory University of Washington, Seattle, Washington More articles by this author Mark A. Bush GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Hui Zhi GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Ralph B. Caricofe GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Alvin M. Matsumoto Geriatric Research Education and Clinical Center, Veterans Affairs-Puget Sound Health Care System, Seattle, Washington Financial interest and/or other relationship with GlaxoSmithKline, Solvay, USADA, Merck, PCC and Up to Date. More articles by this author Ronald S. Swerdloff Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California More articles by this author Christina Wang Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California Financial interest and/or other relationship with Clarus Therapeutics. More articles by this author Richard V. Clark GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina Financial interest and/or other relationship with GlaxoSmithKline. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2015348574 created "2016-06-24" @default.
• W2015348574 creator A5008434600 @default.
• W2015348574 creator A5014394910 @default.
• W2015348574 creator A5017240945 @default.
• W2015348574 creator A5052592209 @default.
• W2015348574 creator A5062259004 @default.
• W2015348574 creator A5071744339 @default.
• W2015348574 creator A5071984726 @default.
• W2015348574 creator A5090807122 @default.
• W2015348574 date "2011-02-01" @default.
• W2015348574 modified "2023-09-29" @default.
• W2015348574 title "Oral Testosterone With and Without Concomitant Inhibition of 5α-Reductase by Dutasteride in Hypogonadal Men for 28 Days" @default.
• W2015348574 cites W1968394900 @default.
• W2015348574 cites W1979844949 @default.
• W2015348574 cites W1987045046 @default.
• W2015348574 cites W1992360428 @default.
• W2015348574 cites W2005563447 @default.
• W2015348574 cites W2006549547 @default.
• W2015348574 cites W2020105514 @default.
• W2015348574 cites W2025503392 @default.
• W2015348574 cites W2028434302 @default.
• W2015348574 cites W2075118988 @default.
• W2015348574 cites W2091054826 @default.
• W2015348574 cites W2116827517 @default.
• W2015348574 cites W2125628942 @default.
• W2015348574 cites W2130039728 @default.
• W2015348574 cites W2135798327 @default.
• W2015348574 cites W2139991044 @default.
• W2015348574 cites W2142478998 @default.
• W2015348574 cites W2150101787 @default.
• W2015348574 cites W2151547940 @default.
• W2015348574 cites W2171711773 @default.
• W2015348574 cites W3135529189 @default.
• W2015348574 cites W4232620432 @default.
• W2015348574 cites W4233478829 @default.
• W2015348574 cites W4246208375 @default.
• W2015348574 cites W4254441152 @default.
• W2015348574 cites W4362207783 @default.
• W2015348574 cites W2043657681 @default.
• W2015348574 doi "https://doi.org/10.1016/j.juro.2010.09.089" @default.
• W2015348574 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4267472" @default.
• W2015348574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21168874" @default.
• W2015348574 hasPublicationYear "2011" @default.
• W2015348574 type Work @default.
• W2015348574 sameAs 2015348574 @default.
• W2015348574 citedByCount "11" @default.
• W2015348574 countsByYear W20153485742012 @default.
• W2015348574 countsByYear W20153485742013 @default.
• W2015348574 countsByYear W20153485742016 @default.
• W2015348574 countsByYear W20153485742017 @default.
• W2015348574 countsByYear W20153485742020 @default.
• W2015348574 countsByYear W20153485742021 @default.
• W2015348574 countsByYear W20153485742023 @default.
• W2015348574 crossrefType "journal-article" @default.
• W2015348574 hasAuthorship W2015348574A5008434600 @default.
• W2015348574 hasAuthorship W2015348574A5014394910 @default.
• W2015348574 hasAuthorship W2015348574A5017240945 @default.
• W2015348574 hasAuthorship W2015348574A5052592209 @default.
• W2015348574 hasAuthorship W2015348574A5062259004 @default.
• W2015348574 hasAuthorship W2015348574A5071744339 @default.
• W2015348574 hasAuthorship W2015348574A5071984726 @default.
• W2015348574 hasAuthorship W2015348574A5090807122 @default.
• W2015348574 hasBestOaLocation W20153485742 @default.
• W2015348574 hasConcept C121608353 @default.
• W2015348574 hasConcept C126322002 @default.
• W2015348574 hasConcept C126894567 @default.
• W2015348574 hasConcept C134018914 @default.
• W2015348574 hasConcept C2775874879 @default.
• W2015348574 hasConcept C2776235491 @default.
• W2015348574 hasConcept C2778878792 @default.
• W2015348574 hasConcept C2779279991 @default.
• W2015348574 hasConcept C2779384505 @default.
• W2015348574 hasConcept C2910366748 @default.
• W2015348574 hasConcept C71924100 @default.
• W2015348574 hasConceptScore W2015348574C121608353 @default.
• W2015348574 hasConceptScore W2015348574C126322002 @default.
• W2015348574 hasConceptScore W2015348574C126894567 @default.
• W2015348574 hasConceptScore W2015348574C134018914 @default.
• W2015348574 hasConceptScore W2015348574C2775874879 @default.
• W2015348574 hasConceptScore W2015348574C2776235491 @default.
• W2015348574 hasConceptScore W2015348574C2778878792 @default.
• W2015348574 hasConceptScore W2015348574C2779279991 @default.
• W2015348574 hasConceptScore W2015348574C2779384505 @default.
• W2015348574 hasConceptScore W2015348574C2910366748 @default.
• W2015348574 hasConceptScore W2015348574C71924100 @default.
• W2015348574 hasIssue "2" @default.
• W2015348574 hasLocation W20153485741 @default.
• W2015348574 hasLocation W20153485742 @default.
• W2015348574 hasLocation W20153485743 @default.
• W2015348574 hasLocation W20153485744 @default.
• W2015348574 hasOpenAccess W2015348574 @default.
• W2015348574 hasPrimaryLocation W20153485741 @default.
• W2015348574 hasRelatedWork W111583749 @default.
• W2015348574 hasRelatedWork W1729580440 @default.
• W2015348574 hasRelatedWork W2020105514 @default.
• W2015348574 hasRelatedWork W2022026066 @default.
• W2015348574 hasRelatedWork W2035004660 @default.

• next